EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Superior Survival and Lower Recurrence Outcomes with Breast-Conserving Surgery Compared to Mastectomy Following Neoadjuvant Therapy in 607 Breast Cancer Patients

Damiano Gentile iD, Jacopo Canzian iD, Erika Barbieri, Simone Di Maria Grimaldi iD, Rita De Sanctis iD, Corrado Tinterri

Cancers · 24.02.2025 · 17 (5) · 766

DOI: 10.3390/cancers17050766 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 24.02.2025. Verfasst von Damiano Gentile und 5 weiteren Autor:innen. Beteiligte Einrichtung: Breast Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Backgrounds: Neoadjuvant therapy (NAT) is a cornerstone in the management of breast cancer (BC), enabling tumor downstaging and improved surgical options.

Methods

This study retrospectively analyzed 607 BC patients treated with NAT and surgery at IRCCS Humanitas Research Hospital, Milan, Italy, to compare long-term oncologic outcomes of breast-conserving surgery (BCS) versus mastectomy. Patient demographics, tumor characteristics, and treatment details were analyzed using descriptive statistics, logistic regression, and Cox proportional hazards models.

Results

Of the 607 patients, 54.7% underwent BCS, and 45.3% had mastectomy. BCS was associated with significantly superior 10-year outcomes compared to mastectomy, including disease-free survival (DFS, 75.2% vs. 71.1%, p = 0.001), distant DFS (75.2% vs. 71.1%, p = 0.001), overall survival (OS, 82.9% vs. 78.1%, p = 0.002), and BC-specific survival (BCSS, 87.7% vs. 83.1%, p = 0.001). Pathologic complete response (pCR) emerged as a protective factor across all endpoints, while mastectomy was independently associated with worse BCSS (HR: 2.068, 95% CI: 1.016–4.210, p = 0.045).

Conclusions

Our findings demonstrate the oncologic safety and potential superiority of BCS over mastectomy in NAT-treated BC patients, highlighting the importance of individualized surgical decision-making to optimize survival outcomes.

Schlagwörter

Stichwörter der Autor:innen

breast cancerbreast-conserving surgerymastectomyneoadjuvant therapy

Autor:innen und Institutionen

  • Breast Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy.
  • Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090 Milan, Italy.
  • Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy.

ORCID-Profile: Damiano Gentile, Jacopo Canzian, Simone Di Maria Grimaldi, Rita De Sanctis

Zitieren

APA

Gentile, D., Canzian, J., Barbieri, E., Di Maria Grimaldi, S., De Sanctis, R., & Tinterri, C. (2025). Superior Survival and Lower Recurrence Outcomes with Breast-Conserving Surgery Compared to Mastectomy Following Neoadjuvant Therapy in 607 Breast Cancer Patients. Cancers, 17(5), 766. https://doi.org/10.3390/cancers17050766

Vancouver

Gentile D, Canzian J, Barbieri E, Di Maria Grimaldi S, De Sanctis R, Tinterri C. Superior Survival and Lower Recurrence Outcomes with Breast-Conserving Surgery Compared to Mastectomy Following Neoadjuvant Therapy in 607 Breast Cancer Patients. Cancers. 2025;17(5):766. doi:10.3390/cancers17050766

BibTeX
@article{Gentile2025,
  author = {Gentile, Damiano and Canzian, Jacopo and Barbieri, Erika and Di Maria Grimaldi, Simone and De Sanctis, Rita and Tinterri, Corrado},
  title = {Superior Survival and Lower Recurrence Outcomes with Breast-Conserving Surgery Compared to Mastectomy Following Neoadjuvant Therapy in 607 Breast Cancer Patients},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {5},
  pages = {766},
  doi = {10.3390/cancers17050766}
}
Kostenlos starten →